MESENCHYMAL STEM CELLS – ADVANCES & APPLICATIONS
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY……….p.12 2. REPORT OVERVIEW………..p.14 2.1 Target Demographic 2.2 Key Findings2.3 Statement of the Report 2.4 Purpose
2.4.1 To Survey Recent MSC Advancements
2.4.2 To Provide a Snapshot” of the Global MSC Market 2.4.3 To Assess Opportunities for Commercialization
2.4.4 To Identify Major Market Players and Assess the Competitive Environment 2.4.5 To Identify Existing and Emerging Trends
2.4.6 To Identify Critical Opportunities and Threats within the MSC Market 3. RESEARCH METHODOLOGY………..p.21 3.1 Input Sources
3.2 Research & Analysis Methodologies
3.3 Criteria for Identiyfing MSC Market Leaders 3.3.1 Size of Company 3.3.2 Type of Product/Services 3.3.2 Degree of Specialization 3.3.4 Patent Positions 3.3.5 Business Reputation 3.3.6 Financial Strength 3.3.7 Partnerships 3.3.8 Certifications
4. MESENCHYMAL STEM CELL (MSC) DEFINITIONS & NOMENCLATURE………...p.24 4.1. Definition
4.2. Alternative Nomenclature 4.2.1 Mesenchymal Stem Cell
4.2.2 Marrow Stromal Cell (or Mesenchymal Stromal Cell) 4.2.3 Multipotent Stromal Cell
4.2.4 Colony-Forming Unit-fibroblasts
5. MSC CRITERIA & CHARACTERISTICS……….………p.27 5.1 Discovery
(FIGURE) Key Dates in the Discovery of Mesenchymal Stem Cells 5.2 Physical Assessment
5.3 Functional Attributes
5.4. Benefits of MSCs Relative to Other Stem Cells
(FIGURE) Benefits of MSCs Relative to Other Stem Cells 5.4.1 Well-Characterized
5.4.2 Non-Controversial
5.4.3 Diverse Differentiation Potential 5.4.4 Ease of Growth in Culture 5.4.5 Flexible Propagation
5.4.6 Clinically Relevant Volumes 5.4.7 Role as Regulatory Cells 5.4.8 Delivery of Gene Products 5.4.9 Favorable Immune Status
6. MSC ISOLATION SOURCES……….p.32 6.1 Adult Sources
(TABLE) Adult Sources for Mesenchymal Stem Cell (MSC) Isolation 6.2 Fetal Sources
(TABLE) Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation
7. COMMERCIAL INTEREST IN MSCs………p.36 (TABLE) Differentiation Capacity of Mesenchymal Stem Cells
7.1 Cell Types Derived from MSCs 7.2 Therapeutic Potential of MSCs
8. INTRODUCTION TO REGENERATIVE MEDICINE (RM) INDUSTRY………p.38 8.1 Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview 8.2 Global Breakdown of Regenerative Medicine (RM) Industry by Region
(TABLE) Global Breakdown of RM Companies by Region (FIGURE) Global Breakdown of RM Companies by Region 8.3 Breakdown of Global RM Companies by Type
(TABLE) Global Breakdown of RM Companies by Type 8.4 Number of RM Clinical Trials by Phase of Development
(TABLE) Number of RM Clinical Trials by Phase 8.5 Major Financial Events in the RM Industry
(TABLE) Major Financial Events in RM Industry in 2014 (FIGURE) Major Financial Events in RM Industry in 2014 8.6 Major Partnerships and Acquisitions in RM Industry
(TABLE) Major Partnerships and Acquisitions in RM Industry in 2014 (FIGURE) Major Partnerships and Acquisitions in RM Industry in 2014 8.7 Major Regulatory Milestones in RM Industry
(TABLE) Major Regulatory Milestones in RM Industry in 2014 (FIGURE) Major Regulatory Milestones in RM Industry in 2014
8.8 Major Pharma and Biotech Companies Active in Advanced Therapies (TABLE) Major Pharma and Biotech Companies Active in Advanced Therapies
(TABLE) Areas of Focus Among Large Pharmaceutical and Biotech Companies Involved with Advanced Therapies
8.9 Major Corporate Partnerships in RM Industry
(TABLE) Major Corporate Partnerships in RM Industry in 2014 8.10 Anticipated Major RM Clinical Events
(TABLE) Anticipated Major RM Clinical Events in 2015
9. INTRODUCTION TO THE STEM CELL THERAPY INDUSTRY……….p.54 9.1 Types of Stem Cells Used in Cell Therapy
9.1.1 Human Embryonic Stem Cells 9.1.2 Induced Pluripotent Stem Cells 9.1.3 Mesenchymal Stem Cells (MSCs) 9.1.4 Hematopoietic Stem Cells 9.1.5 Adipose Stem Cells (ASCs) 9.1.6 Neural Stem Cells (NSCs)
(TABLE) Different Types of Stem Cells Used in Cell Therapy and their Characteristics 9.2 Types of Stem Cells Used in Cell Therapy, by Differentiation Potential
(FIGURE) Five Types of Stem Cells, by Differentiation Potential 9.2.1 Totipotent (or Omnipotent) Stem Cells
9.2.2 Pluripotent Stem Cells 9.2.3 Multipotent Stem Cells 9.2.4 Oligopotent stem cells 9.2.5 Unipotent Stem Cells
10. CELL THERAPY (CT) PRODUCTS: SUCCESSES AND FAILURES…….…………p.60 10.1 Cell Therapy Product Candidates in Late-Stage Clinical Development
(TABLE) Mesenchymal Stem Cell Product Candidates in Late-Stage Clinical Development 10.2 Cell Therapy Products Being Developed for Cardiovascular Indication
10.3 Cell Therapy Products Being Developed for Other Indications 10.4 Major Commercially Available Cell Therapy Products
10.5 Cell Therapy Products Approved in South Korea
(TABLE 13) Cell Therapy Products Approved in South Korea 10.6 Major Cell Therapies in Phase III
10.6.1 Prochymal
10.6.2 Mesenchymal Precursor Cell (MPC) 10.6.3 MyoCell 10.6.4 Ixmyelocel-T 10.6.5 ELAD 10.6.6 HP802 10.6.7 StemEx (Carlecortemcel-L) 10.6.8 LaViv 10.6.9 GSK 2696273 10.6.10 Renew 10.6.11 NT-501 (Renexus) 10.6.12 Neocart 10.6.13 DeNovo ET 10.6.14 MACI
10.7 Clinical Trial Failures in Cell Therapy 10.7.1 Failure of Phase II for MultiStem 10.7.2 Failure of Cardio 133 Trial
10.7.3 Termination of AlloCure’s ACT-AKI Trial 10.7.4 Failed Stroke Trial in India
10.7.5 Failure of HeartiCellGram-AMI Trial 10.7.6 Failure of Adipose MSCs in ARDS 10.7.7 CD133+ in CLI Not Feasible
10.7.8 Failed MSC Trial for Multiple Sclerosis 10.7.9 Failure of Chinese Diabetes Trial
10.7.10 Failed Efficacy Trial in AMI by Stempeucel
10.7.11 Involvement of Multinational Companies (MNCs) in Cell Therapy Sector (TABLE) Major Companies and Products in Development within Cell Therapy Sector 11. THE MARKET FOR MESENCHYMAL STEM CELL THERAPIES………..p.74 11.1 Market Potential – All Stem Cell Types
11.2. Market Potential – Mesenchymal Stem Cells 11.3 Global Market for Stem Cells by Disease Indication
(TABLE) Global Market for Stem Cell Therapies by Disease Indication, Through 2021 (FIGURE) Global Market for Stem Cell Therapies by Disease Indication, Through 2021 12. RESEARCH AND THERAPEUTIC APPLICATIONS OF MSCs………..p.78 (TABLE) MESENCHYMAL STEM CELL RESEARCH APPLICATIONS
12.1 Basic Research Applications 12.1.1 MSC Morphology 12.1.2 MSC Detection
12.1.3 Differentiation Capacity 12.1.4 Immuno-modulatory Effects
12.2 Cell Transplantation for Site-Specific Repair 12.2.1 Osteochondral Repair
12.2.2 Myogenic and Myocardial Repair 12.2.3 Neural Repair
12.3 Directed Differentiation of Mesenchymal Stem Cells
12.3.1 Directed Differentiation of MSCs into Intra-Mesenchymal Lineages 12.3.2 Directed Differentiation of MSCs into Extra-Mesenchymal Lineages 12.4 Drug Delivery Applications: Engineered MSCs as Carriers of Anti-Cancer Drugs 12.5 Drug Screening
12.6 Gene Transfer Studies
12.7 MSC-Mediated Inhibition of Immune Effector Cells 12.8 Supporting Hematopoietic Cell Applications 12.9 Use of 3-D Scaffolds for Tissue Engineering
12.10 Topical Therapy and Use of MSCs in Wound Healing
13. MSC PRODUCT DEVELOPMENT VARIABLES – ATTRIBUTES & ACQUISITION…..p.94 13.1 Biological Properties of MSCs Contributing to Therapeutic Effects
13.1.1 MSCs’ Capacity to Migrate and Engraft 13.1.2 MSCs’ Differentiation Potential
(TABLE) Origin and Cell Types Derived from MSCs
13.1.3 MSCs’ Potential to Secrete Multiple Bioactive Molecules
(TABLE) Important Bioactive Molecules Secreted by MSCs and Their Functions 13.1.4 MSCs’ Potential for Immunomodulatory Functions
(TABLE) Immunomodulatory Effects of MSCs on Immune Cells 13.1.5 Variable Immunophenotype of MSCs
(TABLE) Cell Surface Antigen Expressions of MSCs Isolated from Different Sources 13.2 Factors Impacting MSCs Acquisition
13.3 Major Clinical Sources of MSCs (TABLE) Major Clinical Sources of MSCs
14. CLINICAL APPLICATIONS OF MESENCHYMAL STEM CELLS………p.100 14.1 Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs)
14.1.1 BMMSCs and Kidney
(TABLE) A Sample of Clinical Trials using BMMSCs for Kidney Diseases 14.1.2 BMMSCs and Pancreas
(TABLE) A Sample of Clinical Trials Using BMMSCs for Diabetes 14.1.3 BMMSCs and Heart
(TABLE) A Sample of Clinical Trials Using BMMSCs for Heart Disease 14.1.4 BMMSCs and Liver
(TABLE) A Sample of Clinical Trials Using BMMSCs for Liver Diseases 14.1.5 BMMSCs and Brain
(TABLE) Clinical and Experimental Therapies Using MSCs for Neural Diseases 14.1.6 BMMSCs and Intestine
(TABLE) A Sample of Clinical Trials Using BMMSCs for Intestinal Diseases 14.1.7 BMMSCs and Bone
(TABLE) A Sample of Clinical Trials Using BMMSCs for Musculoskeletal Diseases 14.2 Adipose-Derived Mesenchymal Stem Cells (ADSCs)
14.2.1 Clinical Appplicationsof Adipose-Derived Mesenchymal Stem Cells (ADSCs) (TABLE) ADSCs Transplantation in Clinical Trials by Region/Country in Phase III 14.2.2 Selected ADSC Secretomes and their Functions
(TABLE) Selected ADSC Secretomes and their Functions
14.3 Mesenchymal Stem Cells (MSCs) Derived from Wharton’s Jelly 14.3.1 Clinical Application Properties of WJ-MSCs
14.3.2 Immunoprivileged Status of WJ-MSCs 14.3.3 Clinical Applications of WJ-MSCs
(TABLE) A Summary of Clinical Trials Using WJ-MSCs 14.4 Umbilical Cord Blood-Derived MSCs (UCBMSCs)
(TABLE) Clinical Trials Using UCBMSCs and Targeted Diseases 14.5 Dominance of MSCs in Cell Therapy Clinical Trials
15. MAJOR DISEASES ADDRESSED BY MSCs IN CURRENT CLINICAL TRIALS……p.112 (TABLE) Clinical Trials Using MSCs by Disease Type, 2014
(FIGURE) Clinical Trials Using MSCs by Disease Type, 2014 15.1 MSCs for Treating Liver Diseases
(TABLE) A Sample of Clinical Trials Using MSCs for Liver Disorders 15.2 MSCs for Neurodegenerative Diseases
(TABLE): A Sample of Clinical Trials Using MSCs for Neurodegenerative Diseases 15.3 Clinical Trials Using MSCs for Autoimmune Diseases
(TABLE) A Sample of Phase I and II Clinical Trials for Autoimmune Diseases as of 2012 15.4 Clinical Trials Using MSCs for Diabetes
(TABLE) A Sample of Clinical Trials Using MSCs for Diabetes 15.5 MSCs for Cardiovascular Repair
(TABLE) A Sample of Clinical Trials Using MSCs for Cardiovascular Diseases 15.6 MSCs for Musculoskeletal Diseases
(TABLE) Clinical Trials Involving MSCs for Bone and Cartilage Repair
15.6.1 Studies Using MSCs for Musculoskeletal Indications by Leading Countries (TABLE) Studies Using MSCs for Musculoskeletal Indications by Country
15.6.2 Application of MSCs in Joint Diseases
(TABLE) A Sample of Current Clinical Trials Using MSCs for Osteoarthritis
(TABLE) A Sample of Clinical Trials Involving MSCs for Bone and Cartilage Repair 15.7 MSCs in Neuron/Spinal Cord Diseases
(TABLE) Sample of Clinical Trials in Different Countries Using MSCs for Neuron and Spinal Cord Diseases
15.8 MSC Infusion for GvHD
(TABLE) Clinical Experience of MSCs in GvHD Treatment 15.9 MSCs for Crohn’s Disease
(TABLE) A Sample of Clinical Trials Using MSCs for Crohn’s Disease 15.10 MSCs in Wound Healing
(TABLE) Clinical Studies using MSCs for Wound Healing 15.11 Increasing Focus on Immunological Properties of MSCs
(TABLE) Number of MSC Scientific Publications about Immune/Inflammation by Year (FIGURE) Number of MSC Scientific Publications about Immune/Inflammation by Year 15.12 Selected MSCs Late-Stage Pipeline Cell Therapies
(TABLE) Selected MSCs Late-Stage Pipeline Cell Therapies
16. MARKET OPPORTUNITIES FOR BIOBANKING OF MESENCHYMAL STEM CELLS...p.128 16.1 Types of Mesenchymal Stem Cell Biobanking
(TABLE) Types of Mesenchymal Stem Cell Biobanking 16.2 Dental Stem Cell Banking (MSC Biobanking)
(TABLE) Companies Offering Dental Stem Cell Storage (Diversified Cord Blood Banks and Specialty Companies)
16.3 Umbilical Cord Tissue (MSC Biobanking) 16.3.1 Definitions
16.3.2 Cord Tissue Market Overview
16.3.3 Comparison of Cord Blood & Cord Tissue Storage
(FIGURE) Comparison of Umbilical Cord Blood vs. Umbilical Cord Tissue
16.3.4 Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs) (TABLE) Medical Conditions Being Investigated for Potential to be Treated with Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
16.3.5 Market Penetration of Cord Tissue within the U.S. (TABLE) U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013 (TABLE) U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015 16.3.6. Pricing of Cord Tissue Storage (Global Analysis) (TABLE) Pricing Structures for Cord Tissue Storage
16.4 Adipose-Derived MSCStorage
(TABLE) Companies Offering Adipose-Derived MSC Storage (Both Diversified Cord Blood Banks and Specialty Companies)
16.5 Other Types of MSCBio-Banking: Placental Tissue, Menstrual Stem Cells, Peripheral Blood Stem Cells, Bone Marrow Stem Cells, and More
17. KEY MARKET METRICS FORF MSCs………..p.141 17.1 Global Breakdown of Mesenchymal Stem Cell Clinical Trials
17.1.1 Breakdown of MSC Clinical Trials, By Phase
FIGURE: Percentage of Mesenchymal Stem Cell (MSC) Clinical Trials by Phase 17.1.2 Additional Resources
17.1.2 Breakdown of MSC Clinical Trials, By Geography (FIGURE) Geographical Assessment of MSC Clinical Trial Activity (TABLE) Geographical Breakdown of MSC Clinical Trial Activity
17.1.3 Types of Sponsoring/Collaborating Organizations Supporting MSC Clinical Trials (TABLE) Breakdown of MSC Clnical Trial Activity by Sponsoring/Collaborating Organization (FIGURE) Breakdown of MSC Clinical Trial Activity by Sponsor/Collaborating Organization
17.1.4 Specific Industry Participants Supporting MSC Clinical Trial Activity (TABLE) Industry Participants Sponsoring/Collaborating on MSC Clinical Trials (TABLE) Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials (FIGURE)Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials 17.1.5. Summary of Findings for Mesenchymal Stem Cell Clinical Trials
17.2 Patent Analysis
17.2.1 Role of Patent Analysis for Competitive Intelligence 17.2.2 MSC Patent Landscape
17.2.3 Methodology of MSC Patent Analysis 17.2.3 MSC Patents Filed in 2015
(TABLE) Mesenchymal Stem Cell Patents Filed in 2015 17.3 Scientific Publication Analysis
(TABLE) Analysis of MSC Scientific Publications per Year (FIGURE) Analysis of MSC Scientific Publications per Year
(FIGURE) 5-Year Projections for MSC Scientific Publication Rates (2016-2020) 17.4 Grant Rate Analysis
17.4.1 All-Time Analysis of MSC Grants (1997 to Present) (TABLE) Number of MSC Grant Rates, by Year (RePORTer Analysis) 17.4.1.1 Year-over-Year Trends in MSC Grants
(TABLE) Number of MSC Projects Funded by NIH Support by Year (TABLE) Amount of Funding for MSC Projects Supported by NIH by Year
17.4.1.2 Geographical Assessment of MSC Grants
(TABLE) Geographical Assessment of MSC Grants Funded by NIH Support 17.4.1.3 Assessment of MSC Grants By Subject Matter (1997 to Present) (GRAPH) Breakdown of MSC Grants Funded by NIH Suppport by Subject Matter 17.4.1.4 Dominant Principal Investigators
(TABLE) Leading Principal Investigators for MSC Research 17.4.2 2015 Analysis of MSC Grants
17.4.2.1 List of MSC Grants Funded by NIH-Support in 2015 Fiscal Year (TABLE) MSC Grants Funded by NIH-Support in 2015 Fiscal Year
17.4.2.2 Assessment of MSC Grants by Subject Matter (2015) (TABLE) Breakdown of MSC Grants Funded by NIH-Support by Subject
18. SOCIAL ANALYTICS FOR MESENCHYMAL STEM CELLS………p.169 18.1 Marketing Cost Analysis: Search Term “Mesenchymal Stem Cell”
18.1.1 Pay-Per-Click Cost for the Search Term “Mesenchymal Stem Cell”
(FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; U.S. Only)
(FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; U.S. Only)
(FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; Geography: Worldwide)
(FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; Geography: Worldwide)
(TABLE) Google Adwords Pay-Per-Click (PPC) Costs for MSCs 18.1.2 Analysis of Derivative Search Terms
(FIGURE) Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: USA Only)
(FIGURE) Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: Worldwide)
18.2 MSC Articles Receiving Most Social Media Shares over Past 12 Months 18.2.1 MSC Specific Analysis
(TABLE) Most Shared MSC Articles of the Past 12 Months 18.2.1 Stem Cell Analysis (All Types)
(TABLE) Most Shared Stem Cell Articles of the Past 12 Months (All Stem Cell Types) 18.3 Google Trend Data for MSCs
18.3.1 Google Trend Data - Mesenchymal Stem Cells Only
(FIGURE) Comparison of Google Trend Data for “Mesenchymal Stem Cells” (Plural) vs. “Mesenchymal Stem Cell” (Singular) over a 10-Year History
(FIGURE) Google Trend Data for “Mesenchymal Stem Cells” over a 5-Year History
(FIGURE) Google Trend Data Showing Regional Interest in “Mesenchymal Stem Cells” over a 5-Year History
(GRAPH) Google Trend Data Showing City-by-City Interest in “Mesenchymal Stem Cells” over a 5-Year History
(TABLE) Google Trend Data Showing Related Searches for “Mesenchymal Stem Cells” over a 5-Year History
(FIGURE) Groundbreaking Years in Hematopoietic Stem Cell Transplant History 19.3.2 Google Trend Data - All Types of Stem Cells
(FIGURE) Google Trend Data for “Stem Cells” over a 10-Year History
(FIGURE) Google Trend Data – Comparison of All Types of Stem Cells over a 5-Year History (FIGURE) Google Trend Data Showing Regional Interest in “Stem Cells” over a 5-Year History (FIGURE) Google Trend Data Showing City-by-City Interest in “Stem Cells” over a 5-Year History (TABLE) Google Trend Data Showing Related Searches for “Stem Cells” over a 5-Year History 18.4 Twitter Hashtag Data
(TABLE) Rates of Twitter Usage by Country
18.4.1 Twitter Hashtag Data – Mesechymal Specific Data (FIGURE) Top 10 Hashtags Related to “#Mesenchymal” on Twitter (TABLE) Top 10 Hashtags Related to “#Mesenchymal” on Twitter 18.4.2 Twitter Hashtag Data – Stem Cells (All Types)
(FIGURE) Top 10 Hashtags Related to “#StemCells” on Twitter (TABLE) Top 10 Hashtags Related to “#StemCells” on Twitter 18.4.3 Top Five MSC Influencers on Twitter
(TABLE) Top 5 MSC Influencers on Twitter
18.4.4 Top Five Stem Cell Influencers on Twitter (TABLE) Top Five Stem Cell Influencers on Twitter
19. SELECTED COMPANY PROFILES………p.195 19.1 American Type Culture Collection Inc. (ATCC)
19.2 Anterogen Co., Ltd. 19.2.1 Cupistem Injection 19.2.2 Queencell
19.3 Apceth GmbH & Co. KG
19.3.1 Apceth’s Research Areas 19.4 BioCardia Inc.
(TABLE) BioCardia’s Product Pipeline Overview 19.5 BioRestorative Therapies Inc.
19.5.1 brtxDISC 19.5.2 ThermoStem 19.6 Bone Therapeutics SA
19.6.1 PREOB 19.6.2 ALLOB
(TABLE) Bone Therapeutics’ Product Pipeline 19.7 BrainStorm Cell Therapeutics Inc.
19.7.1 NurOwn
19.8 CellGenix Technologie Transfer GmbH 19.9 Celprogen Inc.
19.10 CellTherapies P/L 19.10.1 Services 19.10.2 Product
19.11 Cesca Therapeutics Inc. 19.11.1 Surgwerks 19.11.2 Cellwerks 19.11.3 AutoXress (AXP) 19.11.4 MarrowXpress (MXP) 19.11.5 Res-Q BMC
19.12 Cyagen Biosciences Inc.
19.12.1 Mesenchymal Stem Cells from Cyagen (TABLE) Cyagen’s Mesenchymal Cells
19.12.2 Adipose-Derived Mesenchymal Stem Cells from Cyagen (TABLE) Cyagen’s Adipose-Derived MSCs
19.12.3 Mesenchymal Stem Cells with GFP from Cyagen (TABLE) Gyagen’s MSCs with GFP
19.12.4 Adipose-Derived Mesenchymal Cells with GFP from Cyagen (TABLE) Adipose-Derived Mesenchymal Cells with GFP
19.12.5 Stem Cell Culture Media from Cyagen (TABLE) Cyagen’s Stem Cell Culture Media
19.12.6 Stem Cell Differentiation Media from Cyagen (TABLE) Cyagen’s Stem Cell Differentiation Media 19.12.7 Primary Cells from Cyagen
(TABLE) Primary Cells from Cyagen
19.12.8 Cyagen’s Cryopreservation Media (TABLE) Cyagen’s Cryopreservation Media 19.12.9 Cyagen’s Primary Cell Culture Media (TABLE) Cyagen’s Primary Cell Culture Media
19.12.10 General Cell Culture Supplements and Specialty Reagents from Cyagen (TABLE) General Cell Culture Supplements and Specialty Reagents from Cyagen
19.13 Cynata Therapeutics Ltd.
19.13.1 Cymerus Platform Technology 19.14 Cytori Therapeutics Inc.
19.14.1 Clinical Trial for Scleroderma 19.14.2 Clinical Trials for Osteoarthritis 19.15 Escape Therapeutics
(TABLE) Escape Therapeutics’ Pipeline Products 19.16 Genlantis
19.17 Kite Pharma Inc.
19.17.1 Engineered Autologous Cell Therapy (eACT) 19.17.2 DC-Ad GM-CAIX
(TABLE) Kite Pharma’s Pipeline and Clinical Trials 19.18 Life Technologies Corporation
19.19 Lonza Group Ltd. 19.19.1 Selected Products 19.20 Medipost Co. Ltd. 19.20.1 Cartistem 19.20.2 Neurostem 19.20.3 Pneumostem 19.21 Mesoblast Ltd.
19.21.1 Mesoblast’s Product Pipeline Overview (TABLE) Mesoblast’s Product Pipeline Overview 19.22 NuVasive Inc.
19.22.1 Osteocel
19.23 Ocata Therapeutics Inc.
(TABLE) Ocata’s Pipeline of Therapeutic Programs 19.24 Organogenesis Inc. 19.24.1 Apligraf 19.24.2 Dermagraft 19.25 Orthofix International N.V. 19.25.1 Trinity Elite 19.25.2 Trinity Evolution
19.26 Osiris Therapeutics Inc. 19.26.1 Grafix
19.26.2 OvationOS 19.26.3 Cartiform
19.27 Pluristem Therapeutics Inc. 19.27.1 PLX Cells
19.28 PromoCell 19.29 Regeneus Ltd.
19.29.1 Products
(TABLE) Regeneus’ Product Pipeline 19.30 ScienCell Research Laboratories 19.31 STEMCELL Technologies Inc. 19.32 Stemedica Cell Technologies Inc.
19.32.1 Stemedyne MSC 19.32.2 Stemedyne NSC 19.32.3 Stemedyne RPE 19.33 Stempeutics Research Pvt. Ltd. 19.33.1 Stempeucel 19.33.2 Stempeutron 19.33.3 Stempeucare
19.34 TiGenix N.V. 19.34.1 Cx601 19.34.2 Cx611 19.34.3 Cx621 19.35 Vericel Corporation
(TABLE) Vericel Corporation’s Product Portfolio
